Skip to main content

Venous and Arterial Thromboembolism among New Users of NuvaRing and Other Combined Hormonal Contraceptives: A Descriptive Analysis

Basic Details
Date Posted
Status
Complete
Medical Product
combined hormonal contraceptives (CHCs)
ethinyl estradiol (EE)
NuvaRing
Health Outcome(s)
arterial thromboembolism (ATE)
venous thromboembolism (VTE)
Description

In this report we examined the characteristics of new users of NuvaRing and other combined hormonal contraceptives (oCHCs) with less than or equal to 20 mcg of ethinyl estradiol (EE) and conducted risk assessment for venous thromboembolism (VTE) and arterial thromboembolism (ATE) in the Sentinel Distributed Database (SDD).

The study period includes data from January 1, 2014 to December 31, 2019. We distributed this request to 15 Data Partners on July 29, 2020.